JC Cutz

The Cost-Effectiveness of Second-Line Crizotinib in Eml4-Alk Rearranged Advanced Non-Small Cell Lung Cancer.

M. Tsao, J. Hoch, D. Graham, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.